Compare INTZ & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | TPST |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 15.6M |
| IPO Year | 2020 | 2012 |
| Metric | INTZ | TPST |
|---|---|---|
| Price | $0.67 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $11.00 |
| AVG Volume (30 Days) | 207.3K | ★ 210.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,015,000.00 | $295,000.00 |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.65 | $0.84 |
| 52 Week High | $2.27 | $12.22 |
| Indicator | INTZ | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 50.24 |
| Support Level | N/A | $1.02 |
| Resistance Level | $0.88 | $1.09 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 13.84 | 45.32 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.